Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut Novo Nordisk was at one point last year Europe's most valuable listed company The Independent UK · Sep 10, 2025
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY). Benzinga · Sep 10, 2025
Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications The Independent UK · Sep 10, 2025
Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly The Guardian - UK · Sep 10, 2025
Trump reportedly asks EU to levy 100% tariffs on India and China; Ozempic maker Novo to cut 9,000 jobs – as it happened US president wants to up pressure on Russia to end war in Ukraine The Guardian - UK · Sep 10, 2025
Ozempic Is The New Botox And Big Pharma Is Printing Billions Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion… Benzinga · Sep 8, 2025
WHO has added GLP-1 drugs to the essential medicines list. Here’s what that means GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too The Independent UK · Sep 5, 2025
Scientists say there is no link between ‘microdosing’ weight-loss drugs and living longer It is ‘too early’ to know whether small doses of weight-loss drugs can help you live longer, experts say The Independent UK · Sep 3, 2025
After Copycat Boom, China's Drugmakers Target Global Generics China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines. Benzinga · Sep 3, 2025
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. Benzinga · Sep 2, 2025
The Ozempic effect: From shopping baskets to dips in Danish GDP As GLP-1 use spreads, grocers and restaurants see lighter baskets, airlines predict fuel savings and health systems eye lower costs—while Denmark sees a clipped GDP. Euronews · Sep 2, 2025
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE:NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points from May's projection. Benzinga · Aug 29, 2025
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers. Benzinga · Aug 28, 2025
Pregnant women face tough choices about medication use due to lack of safety data − here’s why medical research cuts will make it worse A panel convened in July 2025 by the Food and Drug Administration sparked controversy by casting doubt about the safety of commonly used antidepressants during pregnancy. But it also raised the broader issue of how little is known about the safety of many medications used in pregnancy, considering the implications… The Conversation · Aug 28, 2025
Benzinga · Aug 25, 2025 FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.
Benzinga · Aug 25, 2025 Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…
Kiplinger · Aug 25, 2025 I'm a Financial Pro: Why You Shouldn't Put All Your Eggs in the Company Stock Basket Limit exposure to your employer's stock, sell it periodically and maintain portfolio diversification to protect your wealth from unexpected events.
The Independent UK · Aug 23, 2025 Voices: British Mounjaro users face a shortage and tripling prices: Think alternatives, not cold turkey COMMENT: With Mounjaro supplies to the UK on pause, and private prescription costs set to exceed £300 from September, it’s worrying news for the half a million Brits already using weight-loss jabs. Here, doctor and epidemiologist Tim Spector assesses alternative options
Benzinga · Aug 22, 2025 Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…
Bored Panda · Aug 21, 2025 People Are Experiencing Such Bad Ozempic Side Effects That It Might Result In $2B In Lawsuits Ozempic reportedly faces around $2 billion in lawsuits that are about its side effects.
Benzinga · Aug 20, 2025 Novo Nordisk Freezes Hiring As Wegovy Faces Copycats Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).
Benzinga · Aug 19, 2025 What's Going On With Hims & Hers Shares Today? Hims Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy.
International Business Times UK · Aug 19, 2025 Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.
Benzinga · Aug 19, 2025 New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.
Benzinga · Aug 19, 2025 Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.